Abivax Shares: Over 2% Decline Despite Clinical Advances for Obefazimod
Abivax shares fell by 2.19% this Wednesday morning, trading at 107 euros after closing at 109.40 euros the previous day. This movement occurs in a context that is favorable from a scientific standpoint, as the biotech company unveiled new clinical data at the ECCO 2026 congress. Over one year, the stock has nevertheless shown a spectacular increase of 1,360%.
Clinical Breakthroughs Announced at ECCO Congress
At the annual ECCO congress held last weekend, the company Abivax communicated the first evidence of antifibrotic activity of obefazimod, its lead drug candidate. This scientific communication also included updated analyses on the clinical efficacy and tolerance profile of the compound in chronic inflammatory bowel diseases. These results expand the therapeutic potential of the molecule beyond its initial indication in ulcerative colitis, suggesting an effect on intestinal fibrosis, a common complication of these pathologies. The biotech's financial schedule anticipates the publication of its annual 2025 results on March 23, an event that will assess the trajectory of cash consumption and funding for the next stages of clinical development.
Technical Analysis of Abivax Stock Performance
Graphically, the Abivax stock price is significantly above its 200-day moving average, which is at 67.14 euros, indicating a firmly entrenched long-term upward trend. The 50-session moving average, at 104.93 euros, currently serves as the first close technical support. However, the Relative Strength Index (RSI) is at 73, crossing the threshold of 70 generally associated with an overbought zone, which signals that the stock might be temporarily under pressure after its exceptional twelve-month run. The most significant resistance is positioned at 112.40 euros, a level the stock has not managed to surpass in its recent attempts. The correction observed this Wednesday morning brings the price back to the median part of its recent fluctuation bands, between the identified support at 93.70 euros and this resistance. The monthly volatility, measured at 10.63%, remains moderate for a biotech sector value, while the negative beta of -0.32 indicates a significant decorrelation from major benchmark indices.
